AN2 Therapeutics, Inc.
ANTX
$1.15
$0.043.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.39% | 19.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.45% | 34.04% | |||
| Operating Income | 37.45% | -34.04% | |||
| Income Before Tax | 39.32% | -41.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.32% | -41.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.32% | -41.57% | |||
| EBIT | 37.45% | -34.04% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 39.54% | -40.76% | |||
| Normalized Basic EPS | 39.55% | -40.63% | |||
| EPS Diluted | 39.54% | -40.76% | |||
| Normalized Diluted EPS | 39.55% | -40.63% | |||
| Average Basic Shares Outstanding | 0.39% | 0.57% | |||
| Average Diluted Shares Outstanding | 0.39% | 0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||